Srpski
Sažetak
Uvod/cilj: Psorijaza je hronična, zapalenjska, recidivirajuća, neinfektivna dermatoza koja utiče na kvalitet života pacijenata. Još uvek nema dovoljno dokaza iz kliničke prakse u vezi efikasnosti biološke terapije koja se koristi u lečenju psorijaze na kvalitet života obolelih. Cilj rada je bio ispitati uticaj biološke terapije na kvalitet života pacijenata sa psorijazom.
Metode: Provedena je prospektivna observaciona studija na Klinici za dermatovenerologiju Univerzitetskog kliničkog centra , Niš u periodu 1. oktobar 2019. -1. mart 2020.g. Ispitano je 29 pacijenata sa psorijazom (11 žena, 18 muškaraca). Klinička slika bolesti procenjena je upotrebom indeksa Psoriasis Area and Severity Index (PASI) kao srednja vrednost ± SD pre lečenja lekovima secukinumab i ustekinumab i nakon 10 nedelja od terapije. Indeks kvaliteta života Dermatology Life Quality Index (DLQI) je određen na početku lečenja i nakon 10 nedelja.
Rezultati: Prosečan uzrast ispitanika je bio 49.69±12.75 godina i u njemu su dominirali muškarci (62.1%). Prosečno trajanje bolesti kod muškaraca je bilo 16.44±10.05 godina, a kod žena - 17.82±12.79 godina. Prosečna vrednost DLQI je pala od 15.62 ± 7.79 na 6.34 ± 7.19 nakon uzimanja biološke terapije. Prosečni skorovi PASI i DLQI značajno su se razlikovali pre i posle sprovođenja terapije (t-test, p <0.0001).
Zаključak: Biološka terapija psorijaze, osim što popravlja kliničku sliku, značajno i brzo poboljšava kvalitet života pacijenata, što treba uzeti u obzir tokom evaluacije njenih prednosti i rizika.
Reference
1. Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM; Global Psoriasis Atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. https://doi.org/10.1136/bmj.m1590
2. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-1315. https://doi.org/10.1016/S0140-6736(20)32549-6
3. Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019; 20(6):1475. https://doi.org/10.3390/ijms20061475
4. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020; 323(19):1945-1960. https://doi.org/10.1001/jama.2020.4006
5. Rønholt K, Iversen L. Old and New Biological Therapies for Psoriasis. Int J Mol Sci. 2017;18(11):2297. https://doi.org/10.3390/ijms18112297
6. Spasić A, Veličković-Radovanović R, Catić-Đorđević A, Stefanović N, Cvetković T. Quality of life in type 2 diabetic patients. Acta Fac Med Naiss 2014; 31(3): 193-200. https://doi.org/10.2478/afmnai-2014-0024
7. Mei YX, Wu H, Zhang HY, Hou J, Zhang ZX, Liao W. et al. Health-related quality of life and its related factors in coronary heart disease patients: results from the Henan Rural Cohort study. Sci Rep 2021; 11(1): 5011. https://doi.org/10.1038/s41598-021-84554-6
8. Kouwenhoven TA, van der Ploeg JAM, van de Kerkhof PCM. Treatment goals in psoriasis from a patient perspective: a qualitative study. J Dermatolog Treat. 2020;31(1):13-17. https://doi.org/10.1080/09546634.2018.1544408
9. Mahmutovic J, Zukic M, Pasalic A, Brankovic S, Jaganjac A, Katana B. Correlation Between Quality of Life and Depression Among Persons Suffering from Psoriasis. Med Arch. 2017;71(5):341-346. https://doi.org/10.5455/medarh.2017.71.341-346
10. Ražnatović M, Bojanić J, Janković S. Kvalitet života obolelih od psorijaze. Biomedicinska istraživanja 2012;3(1):60-67. http://dx.doi.org//10.7251/bii1201060r
11. Zweegers J, Otero ME, van den Reek JM, Driessen RJ, Kievit W, Seyger MM. et al. Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: a systematic review. Acta Derm Venereol 2016; 96:453–8. https://doi.org/10.2340/00015555-2276
12. van Lümig PP, van de Kerkhof PC, Boezeman JB, Driessen RJ, de Jong EM. Adalimumab therapy for psoriasis in real‐world practice: efficacy, safety and results in biologic‐naïve vs. non‐naïve patients. J Eur Acad Dermatol Venereol 2013; 27:593–600. https://doi.org/10.1111/j.1468-3083.2012.04496.x
13. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210–16. https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
14. Badia X, Mascaro JM, Lozano R. Measuring health‐related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. Br J Dermatol 1999; 141: 698–702. https://doi.org/10.1046/j.1365-2133.1999.03112.x
15. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659-64. https://doi.org/10.1111/j.0022-202X.2005.23621.x
16. Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015; 230(1):27-33. https://doi.org/10.1159/000365390
17. Frieder J, Kivelevitch D, Fiore CT, Saad S, Menter A. The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.Expert Rev Clin Immunol. 2018;14(1):1-19. https://doi.org/10.1080/1744666X.2018.1401468
18. Norris D, Photiou L, Tacey M, Dolianitis C, Varigos G, Foley P, Baker C. Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population. J Dermatolog Treat. 2017;28(8):731-736. https://doi.org/10.1080/09546634.2017.1329501
19. Foley P, Spelman L, Murrell DF, Mate E, Tronnberg R, Lowe PM. Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study. Australas J Dermatol. 2022 ;63(3):312-320. https://doi.org/10.1111/ajd.13893
20. Iskandar IYK, Ashcroft DM, Warren RB, Lunt M, McElhone K, Smith CH. et al. Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. Br J Dermatol. 2017;177(5):1410-1421. https://doi.org/10.1111/bjd.15531
21. Jungo P, Maul JT, Djamei V, von Felten S, Kolios AGA, Czernielewsk J. et al. Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry. Dermatology. 2016;232(6):655-663. https://doi.org/10.1159/000455042
22. Hjalte F, Carlsson KS, Schmitt-Egenolf M. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register. Br J Dermatol. 2018;178(1):245-252. https://doi.org/10.1111/bjd.15757